Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
Lynas CEO Amanda Lacaze to Retire After 12 Years as Rare Earths Demand Grows 
AFT Leaves X Over AI-Generated Images of Minors 
Trump Pushes Tech Giants to Absorb AI Data Center Power Costs, Citing Microsoft Changes 
Saks Global Files for Bankruptcy Protection Amid Mounting Luxury Retail Pressures 
AbbVie Commits $100 Billion to U.S. Investment in Drug Pricing Deal With Trump Administration 
SK Hynix to Invest $13 Billion in Advanced Chip Packaging Plant as AI Memory Demand Surges 
Rio Tinto–Glencore Talks Spark Pressure on BHP as Copper Fuels Mining Mega Deals 
Tesla, EEOC Move Toward Mediation in Racial Harassment Lawsuit 
Trump Considers Starlink to Restore Internet Access in Iran Amid Protests 
Coca-Cola Shelves Costa Coffee Sale After Low Private Equity Offers 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Starlink Internet Remains Active in Iran Despite Nationwide Blackout 
Netflix Plans All-Cash Bid for Warner Bros Discovery Studios Amid Intense Hollywood Takeover Battle 
BESI Reports Strong Q4-25 Orders Surge Driven by Data Center and Hybrid Bonding Demand 
Anthropic Launches HIPAA-Compliant Healthcare Tools for Claude AI Amid Growing Competition 
Alphabet Stock Poised for Growth as Bank of America Sees Strong AI Momentum Into 2026 
GAITHERSBURG, Md., March 31, 2017 -- Emergent BioSolutions Inc. (NYSE:EBS) today announced that it has signed a modification to its contract with the Biomedical Advanced Research and Development Authority (BARDA) to manufacture and store bulk drug substance for its botulism antitoxin, BAT® [Botulism Antitoxin Heptavalent (A, B, C, D, E, F, G) - (Equine)], valued at approximately $53 million with a five-year period of performance. This modification to the contract will enable future filling and deliveries of final drug product to the Strategic National Stockpile (SNS). BAT is indicated for the treatment of symptomatic botulism following documented or suspected exposure to botulinum neurotoxin serotypes A, B, C, D, E, F, or G in adults and pediatric patients.
“Emergent is proud to be a longstanding partner to the U.S. government in providing first-in-class and only-in-class products that address biological threat agents,” said Adam Havey, executive vice president, business operations at Emergent BioSolutions. “This modification to the contract represents the U.S. government’s continued commitment to developing critical countermeasures such as BAT that address public health threats and fulfill its preparedness needs.”
Emergent has been supplying BAT to the SNS under contract HHSO100200600017C, which was signed in 2006 with BARDA, within the Office of the Assistant Secretary for Preparedness and Response, in the U.S. Department of Health and Human Services. BAT is the only botulism antitoxin licensed by the U.S. Food and Drug Administration and distributed from the Centers for Disease Control and Prevention for treating naturally occurring, non-infant botulism, and for administration under emergency conditions.
About Emergent BioSolutions
Emergent BioSolutions Inc. is a global life sciences company seeking to protect and enhance life by focusing on providing specialty products for civilian and military populations that address accidental, intentional, and naturally emerging public health threats. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025. Additional information about the company may be found at emergentbiosolutions.com. Follow us @emergentbiosolu.
Investor Contact: Robert G. Burrows Vice President, Investor Relations 240-631-3280 [email protected] Media Contact: Tracey Schmitt Lintott Senior Vice President, Global Public Affairs 240-631-3281 [email protected]
